July 9, 2019
Mayo experts provide insights into how genes affect medication response
By Sharon Rosen
Pharmacogenomics – how a person’s genes affect medication response – is touching virtually every area of medical care. Findings from the Mayo Clinic RIGHT study (Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment) showed that 99% of participants had at least one genetic variant that may affect their response to medications. […]
Tags: #addiction, #anti-seizure medication, #Center for Individualized Mediicine, #Dr. Lauren Cornell, #Dr. Sanjay Bagaria, #Dr. William Freeman, #Dr. William Palmer, #drug-gene interactions, #epilepsy, #estrogen receptor positive breast cancer, #medical education, #neurological diseases
February 13, 2018
New international practice guidelines for using tamoxifen to treat breast cancer
An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics. Tamoxifen is a hormonal agent used for the prevention and treatment of premenopausal and postmenopausal breast cancer that is estrogen receptor positive. […]
Tags: #CIMCon18, #clinical guidelines, #Clinical Pharmacogenetics Implementation Consortium, #CYP2D6 geneotype, #estrogen receptor positive breast cancer, #tamoxifen, #targeted therapies, breast cancer, center for individualized medicine, DNA Sequencing, Dr. Matthew Goetz, Genetic Testing